drugset / Trial / NCT07243691
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma
Timeline
- Start
- 2025-12-01
- Primary completion
- 2027-11-01
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |